NAGE Niagen Bioscience, Inc.
$2.50▲ +2.46%
ConsumerStaples
Other
Volume 473.5K
Avg Volume (10D) 529.0K
Key Metrics & Fundamentals
Market Cap
$197.82M
P/E Ratio
13.2
Div Yield
0.00%
52W Range
2.39 - 7.95
% vs 50 MA
-13.77%
% vs 200 MA
-37.12%
RSI-14
37.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.32
Free Cash Flow
$2.68M
Gross Rev
$29.79M
Gross Profit
$19.31M
EBITDA
$1.17M
COGS
$10.47M
Operating Exp
$18.61M
Operating Income
$700,000
EBIT
$700,000
Pretax Income
$1.07M
Net Income
$963,000
EPS (Diluted)
0.01
Price & Volume History
Loading chart…
Recent News
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Business Wire · Oct 22, 2026 8:38 AM ET
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Business Wire · Oct 20, 2026 8:32 AM ET
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Business Wire · Oct 15, 2026 8:32 AM ET
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
Business Wire · Oct 8, 2026 8:32 AM ET
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
Business Wire · Oct 6, 2026 8:32 AM ET
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
Business Wire · Oct 1, 2026 8:32 AM ET
Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth?
Insider Monkey · Sep 30, 2026 12:59 PM ET
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Business Wire · Sep 30, 2026 8:32 AM ET
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
Business Wire · Sep 21, 2026 8:32 AM ET
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Business Wire · Sep 17, 2026 8:32 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NAGE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.